Maxim Group Upgrades Akari Therapeutics (AKTX) to Buy
Tweet
Share
E-mailGet Alerts AKTX Hot Sheet
Price: $10.05 --0%
Rating Summary:
7 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 4 | Down: 5 | New: 28
Rating Summary:
7 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 4 | Down: 5 | New: 28
Join SI Premium – FREE
Maxim Group analyst Jason McCarthy upgraded Akari Therapeutics (NASDAQ: AKTX) from Hold to Buy with a price target of $30.00.
For an analyst ratings summary and ratings history on Akari Therapeutics click here. For more ratings news on Akari Therapeutics click here.
Shares of Akari Therapeutics closed at $11.01 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cantor Fitzgerald Starts Enhanced Group Inc. (ENHA) at Overweight
- Celldex Therapeutics (CLDX) PT Raised to $57 at Morgan Stanley
- On Holding AG (ONON) PT Raised to $40 at Needham, 'Bullish Analyst Day Alleviates Growth-Slowdown Fears'
Create E-mail Alert Related Categories
UpgradesRelated Entities
Maxim Group, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
